Medicus Pharma Ltd MDCX 深 沪
已收盘 06-26 16:00:00 美东时间
0.458
+0.013
+2.92%
华盛通- 最 高0.4798
- 今 开0.46
- 成交量 186.50万股
- 最 低 0.4401
- 昨 收 0.445
- 总市值 2594.94万
- 52周最高 3.69
- 市盈率 静 --
- 换手率 3.29%
- 52周最低 0.25
- 委 比 16.14%
- 总股本 5665.82万
- 历史最高 8.94
- 量 比 0.47
- 振 幅 8.92%
- 历史最低 0.25
- 每 手 1
- 风险率 0.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Medicus Pharma To Present Showcase SkinJect Registrational Strategy, Teverelix Precision Medicine Program At 2026 Bio International Conference
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it will participate in the 2026 Bio International Conference, being hel...
06-22 19:37
Medicus Pharma Submits IND Application To DOH For PRECISION-E2, Phase 2a Genomics-Enabled Clinical Trial Evaluating Teverelix In Women With Symptomatic Endometriosis In UAE
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced submission of an Investigational New Drug (IND) application to the Department...
06-11 19:34
Medicus Pharma submits IND to Abu Dhabi health regulator for Teverelix endometriosis trial
Medicus Pharma submits IND to Abu Dhabi health regulator for Teverelix endometriosis trial Medicus Pharma submitted an IND application to Abu Dhabi’s Department of Health for its PRECISION-E2 Phase 2a Teverelix study in endometriosis. The genomics-enabled trial plans to enroll about 84 women in the
06-11 19:30
Medicus Pharma Submits Protocol SKNJCT-005 To FDA Under Existing IND Application, For SkinJect Into Registrational Development For Patients With Gorlin Syndrome
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today
06-03 20:06
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
Medicus Pharma submitted a Phase 2b protocol to the FDA for SkinJect®, targeting patients with Gorlin Syndrome, a rare genetic disorder causing multiple basal cell carcinomas. The study aims to assess efficacy and safety, potentially leading to FDA approval as the first lesion-directed therapy for this population. The company also applied for Orphan Drug Designation and Rare Pediatric Disease Priority Review Voucher, which could expedite approval...
06-03 12:00
Medicus Pharma Receives $22M In Non-Dilutive Financing
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today
05-28 20:19
Medicus Pharma Q1 EPS $(0.31) Misses $(0.19) Estimate
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.19) by 63.16 percent. This is a 26.19 percent increase over losses of $(0.42) per share from
05-15 04:34
Medicus Pharma Highlights Results From Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis; Says Data Reveal 'a clear and consistent dose-response relationship across endpoints'
200μg Cohort Achieves 55% Complete Response at Day 57 Emerging asRegistrational Grade Lead RegimenThe pre-specified expanded dataset analysis builds on this foundation by: Revealing a clear and consistent dose-response
05-06 19:16
Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the company for $11.75 billion, $2 higher than current price.
04-27 16:45
美股夜盘 | Aditxt, Inc.涨34.85%，Intellia Therapeutics, Inc.涨24.21%
Cheetah Net Supply Chain Service, Inc. Class A涨-24.71%；香颂国际涨-17.80%；Homology Medicines, Inc.涨-13.02%
04-27 08:05
